• Bogers JPAM, Hambarian G, Michiels M, Vermeulen J, de Haan L. Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in patients with chronic schizophrenia. A systematic review and meta-analysis. Schizophr Bull [Internet]. 2020 Mar 2;sgaa002. Available from: https://pubmed.ncbi.nlm.nih.gov/32118277. This is a comprehensive and recent review and meta-analysis highlighting many risk factors associated with relapse, particularly around medication non-adherence and specific thresholds for antipsychotic dose reduction.
Fusar-Poli P, Cappucciati M, Bonoldi I, Hui LMC, Rutigliano G, Stahl DR, et al. Prognosis of brief psychotic episodes: a meta-analysis. JAMA psychiatry [Internet]. 2016 Mar;73(3):211–20 Available from: https://pubmed.ncbi.nlm.nih.gov/26764163.
Fusar-Poli P, McGorry PD, Kane JM. Improving outcomes of first-episode psychosis: an overview. World Psychiatry [Internet]. 2017;16(3):251–65 Available from: https://pubmed.ncbi.nlm.nih.gov/28941089.
Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2.
Moncrieff J, Crellin NE, Long MA, Cooper RE, Stockmann T. Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: a systematic review. Schizophr Res [Internet]. 2019;S0920–9964(19):30391–3 Available from: https://pubmed.ncbi.nlm.nih.gov/31604607.
Lal S, Malla A, Marandola G, Thériault J, Tibbo P, Manchanda R, et al. “Worried about relapse”: family members’ experiences and perspectives of relapse in first-episode psychosis. Early Interv Psychiatry. 2019;13(1):24–9.
Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012;139(1–3):116–28.
•• Zhang T, Xu L, Li H, Woodberry KA, Kline ER, Jiang J, et al. Calculating individualized risk components using a mobile app-based risk calculator for clinical high risk of psychosis: findings from ShangHai at risk for psychosis (SHARP) program. Psychol Med [internet]. 2019;16:1–8 Available from: https://pubmed.ncbi.nlm.nih.gov/31839016. This is one of the first smartphone-based risk calculators to exhibit moderate to high sensitivity and specificity for relapse.
Olivares JM, Sermon J, Hemels M, Schreiner A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry [Internet]. 2013;12(1):32 Available from: https://pubmed.ncbi.nlm.nih.gov/24148707.
Zipursky RB, Odejayi G, Agid O, Remington G. You say “schizophrenia” and I say “psychosis”: just tell me when I can come off this medication. Schizophr Res 2020 Feb;
Lee BJ, Kim S-W, Kim JJ, Yu J-C, Lee KY, Won S-H, et al. Defining treatment response, remission, relapse, and recovery in first-episode psychosis: a survey among Korean experts. Psychiatry Investig. 2020;17(2):163–74.
Wang D, Gopal S, Baker S, Narayan VA. Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophr. 2018;4(1):10.
Keks NA, Hope J, Adamopoulos V, Pring W, Tofler D, Macfarlane S, et al. Characteristics, diagnoses and risk profiles of inpatients readmitted within 28 days of discharge to an Australian private psychiatric hospital. Australas psychiatry Bull R Aust New Zeal Coll Psychiatr. 2020;1039856220901469.
Porcelli S, Bianchini O, De Girolamo G, Aguglia E, Crea L, Serretti A. Clinical factors related to schizophrenia relapse. Int J Psychiatry Clin Pract. 2016;20(2):54–69.
Bergé D, Mané A, Salgado P, Cortizo R, Garnier C, Gomez L, et al. Predictors of relapse and functioning in first-episode psychosis: a two-year follow-up study. Psychiatr Serv. 2016;67(2):227–33.
Koutra K, Triliva S, Roumeliotaki T, Basta M, Simos P, Lionis C, et al. Impaired family functioning in psychosis and its relevance to relapse: a two-year follow-up study. Compr Psychiatry. 2015;62:1–12.
Saito Y, Sakurai H, Kane JM, Schooler NR, Suzuki T, Mimura M, et al. Predicting relapse with residual symptoms in schizophrenia: a secondary analysis of the PROACTIVE trial. Schizophr Res [Internet]. 2019/10/28. 2020;215:173–180. Available from: https://pubmed.ncbi.nlm.nih.gov/31672387
Glick ID, Zamora D, Davis JM, Suryadevara U, Goldenson A, Kamis D. Are patients with schizophrenia better off with lifetime antipsychotic medication?: replication of a naturalistic, long-term, follow-up study of antipsychotic treatment. J Clin Psychopharmacol. 2020;40(2):145–8.
García S, Martínez-Cengotitabengoa M, López-Zurbano S, Zorrilla I, López P, Vieta E, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016;36(4):355–71.
Phan SV. Medication adherence in patients with schizophrenia. Int J Psychiatry Med. 2016;51(2):211–9.
Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49(2):196–201.
Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H. Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta-analysis. CNS Drugs 2020 Mar;
Faurholt-Jepsen M, Frost M, Christensen EM, Bardram JE, Vinberg M, Kessing LV. Validity and characteristics of patient-evaluated adherence to medication via smartphones in patients with bipolar disorder: exploratory reanalyses on pooled data from the MONARCA I and II trials. Evid Based Ment Health [Internet]. 2020 Feb;23(1):2–7 Available from: https://pubmed.ncbi.nlm.nih.gov/32046986.
Tessier A, Dupuy M, Baylé FJ, Herse C, Lange A-C, Vrijens B, et al. Brief interventions for improving adherence in schizophrenia: a pilot study using electronic medication event monitoring. Psychiatry Res [Internet]. 2020 Jan 15;112780. Available from: https://pubmed.ncbi.nlm.nih.gov/31954541
Fozoonmayeh D, Le HV, Wittfoth E, Geng C, Ha N, Wang J, et al. A scalable smartwatch-based medication intake detection system using distributed machine learning. J Med Syst [Internet]. 2020 Feb 28;44(4):76. Available from: https://pubmed.ncbi.nlm.nih.gov/32112271
Van Biesen W, Decruyenaere J, Sideri K, Cockbain J, Sterckx S. Remote digital monitoring of medication intake: methodological, medical, ethical and legal reflections. Acta Clin Belg [Internet]. 2019;23:1–8 Available from: https://pubmed.ncbi.nlm.nih.gov/31870225.
Conley RR. The burden of depressive symptoms in people with schizophrenia. Psychiatr Clin North Am. 2009;32(4):853–61.
Müller N. Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry. 2004;37(Suppl 2):S141–7.
Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller H-J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol psychiatry Off J World Fed Soc Biol Psychiatry. 2005;6(3):132–91.
Winklbaur B, Ebner N, Sachs G, Thau K, Fischer G. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci. 2006;8(1):37–43.
Levy E, Pawliuk N, Joober R, Abadi S, Malla A. Medication-adherent first-episode psychosis patients also relapse: why? Can J Psychiatr. 2012;57(2):78–84.
Ortiz-Medina MB, Perea M, Torales J, Ventriglio A, Vitrani G, Aguilar L, et al. Cannabis consumption and psychosis or schizophrenia development. Int J Soc Psychiatry. 2018;64(7):690–704.
Wisdom JP, Manuel JI, Drake RE. Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment. Psychiatr Serv. 2011;62(9):1007–12.
• Weibell MA, Hegelstad WTV, Auestad B, Bramness J, Evensen J, Haahr U, et al. The effect of substance use on 10-year outcome in first-episode psychosis. Schizophr Bull. 2017;43(4):843–51 This study examined substance use in first episode psychosis with a 10-year follow-up and demonstrated important windows for addressing abuse due to the longitudinal nature of the study.
Kazemi DM, Borsari B, Levine MJ, Li S, Lamberson KA, Matta LA. A systematic review of the mHealth interventions to prevent alcohol and substance abuse. J Health Commun. 2017;22(5):413–32.
Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184:346–51.
Moeller KE, Shireman TI, Liskow BI. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. J Clin Psychiatry. 2006;67(12):1942–7.
Fond G, Bulzacka E, Boucekine M, Schürhoff F, Berna F, Godin O, et al. Machine learning for predicting psychotic relapse at 2 years in schizophrenia in the national FACE-SZ cohort. Prog Neuropsychopharmacol Biol Psychiatry [Internet]. 2018/12/12. 2019 Jun 8;92:8–18. Available from: https://pubmed.ncbi.nlm.nih.gov/30552914
Hariman K, Cheng KM, Lam J, Leung SK, Lui SSY. Clinical risk model to predict 28-day unplanned readmission via the accident and emergency department after discharge from acute psychiatric units for patients with psychotic spectrum disorders. BJPsych open [Internet]. 2020;6(1):e13–3 Available from: https://pubmed.ncbi.nlm.nih.gov/31987061.
Birnbaum ML, Ernala SK, Rizvi AF, Arenare E, Van Meter AR, De Choudhury M, et al. Detecting relapse in youth with psychotic disorders utilizing patient-generated and patient-contributed digital data from Facebook. NPJ Schizophr. 2019;5(1):17.
•• Barnett I, Torous J, Staples P, Sandoval L, Keshavan M, Onnela J-P. Relapse prediction in schizophrenia through digital phenotyping: a pilot study. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2018; This is one of the first studies to use anomaly detection on digital phenotyping data to predict a relapse event in an individual with schizophrenia.
Eisner E, Bucci S, Berry N, Emsley R, Barrowclough C, Drake RJ. Feasibility of using a smartphone app to assess early signs, basic symptoms and psychotic symptoms over six months: a preliminary report. Schizophr Res. 2019;208:105–13.
Spaniel F, Vohlídka P, Hrdlicka J, Kozený J, Novák T, Motlová L, et al. ITAREPS: information technology aided relapse prevention programme in schizophrenia. Schizophr Res. 2008;98(1–3):312–7.
Cella M, He Z, Killikelly C, Okruszek Ł, Lewis S, Wykes T. Blending active and passive digital technology methods to improve symptom monitoring in early psychosis. Early Interv Psychiatry [Internet]. 2019;13(5):1271–5 Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/eip.12796.
Torous J, Wisniewski H, Bird B, Carpenter E, David G, Elejalde E, et al. Creating a digital health smartphone app and digital phenotyping platform for mental health and diverse healthcare needs: an interdisciplinary and collaborative approach. J Technol Behav Sci [Internet]. 2019 Apr; Available from: https://doi.org/10.1007/s41347-019-00095-w.
Wisniewski H, Henson P, Torous J. Using a smartphone app to identify clinically relevant behavior trends via symptom report, cognition scores, and exercise levels: a case series [Internet]. Frontiers in Psychiatry. 2019;10:652 Available from: https://www.frontiersin.org/article/10.3389/fpsyt.2019.00652.
Torous JB, Chan SR, Gipson SY-MT, Kim JW, Nguyen T-Q, Luo J, et al. A hierarchical framework for evaluation and informed decision making regarding smartphone apps for clinical care. Psychiatr Serv. 2018;69(5):498–500.
Lagan S, Aquino P, Emerson MR, Fortuna K, Walker R, Torous J. Actionable health app evaluation: translating expert frameworks into objective metrics. npj Digit Med. 2020; forthcoming.
App Evaluation Model [Internet]. [cited 2020 Jun 30]. Available from: https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/app-evaluation-model